A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis.

María SerenoAna María Jimenez-GordoJavier BaenaCarlos AguadoXabier MielgoAna PertejoRosa Álvarez-ÁlvarezAna SánchezJose Luis LópezRaquel MolinaAna López-AlfonsoBerta HernándezLuis Enrique ChiaraAna Manuela MartínAna López-MartínMiriam DortaAna Collazo-LorduyEnrique CasadoAna Ramirez de MolinaGonzalo Colmenarejo

Published in: Cancers (2021)

Our findings suggest that a prolonged G-CSF treatment could be disadvantageous for these cancer patients with infections by COVID-19, with a higher probability of worse outcome.

Keyphrases

coronavirus disease
sars cov
papillary thyroid
squamous cell
respiratory syndrome coronavirus
peripheral blood
cross sectional
cerebrospinal fluid
clinical trial
young adults